View in EDS

Discovery of a Highly Selective NAMPT Inhibitor That Demonstrates Robust Efficacy and Improved Retinal Toxicity with Nicotinic Acid Coadministration.

Saved in:
Bibliographic Details
Title: Discovery of a Highly Selective NAMPT Inhibitor That Demonstrates Robust Efficacy and Improved Retinal Toxicity with Nicotinic Acid Coadministration.
Authors: Zhao G; Cancer Research, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana. Zhao_Genshi@Lilly.com., Green CF; Toxicology, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana., Hui YH; Drug Disposition, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana., Prieto L; Discovery Chemistry Research, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana., Shepard R; Cancer Research, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana., Dong S; Cancer Research, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana., Wang T; Cancer Research, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana., Tan B; Toxicology, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana., Gong X; Cancer Research, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana., Kays L; Cancer Research, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana., Johnson RL; Toxicology, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana., Wu W; Cancer Research, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana., Bhattachar S; Product Design and Developability, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana., Del Prado M; Discovery Chemistry Research, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana., Gillig JR; Discovery Chemistry Research, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana., Fernandez MC; Discovery Chemistry Research, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana., Roth KD; Discovery Chemistry Research, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana., Buchanan S; Cancer Research, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana., Kuo MS; Discovery Chemistry Research, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana., Geeganage S; Cancer Research, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana., Burkholder TP; Discovery Chemistry Research, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana.
Source: Molecular cancer therapeutics [Mol Cancer Ther] 2017 Dec; Vol. 16 (12), pp. 2677-2688. Date of Electronic Publication: 2017 Oct 20.
Publication Type: Journal Article
Journal Info: Publisher: American Association for Cancer Research, Inc Country of Publication: United States NLM ID: 101132535 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1538-8514 (Electronic) Linking ISSN: 15357163 NLM ISO Abbreviation: Mol Cancer Ther Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1538-8514
DOI:10.1158/1535-7163.MCT-16-0674